FindTrial
Sign In

Carvedilol (drug) for liver disease

Acute Hemodynamic Response to Carvedilol in Predicting Survival in Acute on Chronic Liver Failure Patients - A Pilot Study

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/01/039527
Enrollment
50
Registered
2022-01-18
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K768- Other specified diseases of liver

Interventions

Intervention1: Carvedilol: Carvedilol 12.5 MG per oral for 3 months Control Intervention1: This is a single arm trial: This is a single arm trial

Sponsors

Institute of Liver and Biliary Sciences
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1) Patients of ACLF (APASL criteria) - jaundice (serum bilirubin � 5 mg/dL and coagulopathy (INR � 1.5) complicated within 4 weeks by clinical ascites and/or encephalopathy in a patient with previously diagnosed or undiagnosed chronic liver disease/cirrhosis. 2) Age 18-70 yrs 3) Baseline HVPG � 12 mmHg.

Exclusion criteria

Exclusion criteria: 1) Contraindications to NSBB (heart rate 2) Portal Vein Thrombosis, 3) Hepatocellular carcinoma, 4) HVOTO, 5) HE grades 2-4, 6) NSBB therapy within 5 days, 7) Pregnancy, 8) Lactation, 9) Planned for LT in the next 12 weeks 10) No consent.

Design outcomes

Primary

MeasureTime frame
Liver transplant free survivalTimepoint: Day 28—

Secondary

MeasureTime frame
Complications [PHT related bleed, AKI, infections, HE] within 90 daysTimepoint: 90 days;Correlation with evolution of AARC scoreTimepoint: 2 weeks;Liver transplant-free survival rate.Timepoint: 90 days—

Countries

India

Contacts

Public ContactDr Chitranshu Vashishtha

Institute of Liver and Biliary Sciences

chitranshuv@gmail.com01146300000

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026